The phase III PERSEUS study—results of which were presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract LBA-1)—evaluated subcutaneous daratumumab in combination with standard-of-care induction/consolidation vs stand-of-care therapy alone in patients with transplant-eligible newly diagnosed multiple myeloma.
